Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Intercept Pharmaceuticals, Inc. (ICPT : NSDQ)
 
 • Company Description   
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.

Number of Employees: 437

 
 • Price / Volume Information   
Yesterday's Closing Price: $17.16 Daily Weekly Monthly
20 Day Moving Average: 1,524,107 shares
Shares Outstanding: 29.71 (millions)
Market Capitalization: $509.88 (millions)
Beta: 1.27
52 Week High: $22.36
52 Week Low: $11.60
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 8.27% 21.94%
12 Week 11.72% 22.83%
Year To Date 5.34% 28.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
305 Madison Avenue
-
Morristown,NJ 07960
USA
ph: 646-747-1000
fax: 646-747-1001
investors@interceptpharma.com http://www.interceptpharma.com
 
 • General Corporate Information   
Officers
Jerome Durso - President and Chief Executive Officer
Paolo Fundar? - Chairman
Andrew Saik - Chief Financial Officer
Rocco Venezia - Senior Vice President
Luca Benatti - Director

Peer Information
Intercept Pharmaceuticals, Inc. (CORR.)
Intercept Pharmaceuticals, Inc. (RSPI)
Intercept Pharmaceuticals, Inc. (CGXP)
Intercept Pharmaceuticals, Inc. (BGEN)
Intercept Pharmaceuticals, Inc. (GTBP)
Intercept Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45845P108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 29.71
Most Recent Split Date: (:1)
Beta: 1.27
Market Capitalization: $509.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.71 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 1.38
EPS Growth
vs. Year Ago Period: 52.46%
vs. Previous Quarter: 52.85%
Sales Growth
vs. Year Ago Period: 8.48%
vs. Previous Quarter: -4.14%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -16.33
12/31/21 - -20.62
09/30/21 - -23.07
Current Ratio
03/31/22 - 3.16
12/31/21 - 3.01
09/30/21 - 3.45
Quick Ratio
03/31/22 - 3.16
12/31/21 - 3.01
09/30/21 - 3.45
Operating Margin
03/31/22 - -22.90
12/31/21 - -29.70
09/30/21 - -34.94
Net Margin
03/31/22 - -18.44
12/31/21 - -25.15
09/30/21 - -30.28
Pre-Tax Margin
03/31/22 - -18.44
12/31/21 - -25.15
09/30/21 - -30.28
Book Value
03/31/22 - -12.51
12/31/21 - -6.23
09/30/21 - -5.28
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©